vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Kennedy-Wilson Holdings, Inc. (KW). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $120.6M, roughly 1.5× Kennedy-Wilson Holdings, Inc.). Kennedy-Wilson Holdings, Inc. runs the higher net margin — 48.1% vs 13.3%, a 34.8% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -11.0%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-55.2M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -6.0%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Kennedy Wilson is a real estate investment company headquartered in Beverly Hills, California, United States.
AMPH vs KW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $120.6M |
| Net Profit | $24.4M | $58.0M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 57.3% |
| Net Margin | 13.3% | 48.1% |
| Revenue YoY | -1.8% | -11.0% |
| Net Profit YoY | -35.7% | 32.7% |
| EPS (diluted) | $0.51 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $120.6M | ||
| Q3 25 | $191.8M | $116.4M | ||
| Q2 25 | $174.4M | $135.7M | ||
| Q1 25 | $170.5M | $128.3M | ||
| Q4 24 | $186.5M | $135.5M | ||
| Q3 24 | $191.2M | $127.5M | ||
| Q2 24 | $182.4M | $132.0M | ||
| Q1 24 | $171.8M | $136.4M |
| Q4 25 | $24.4M | $58.0M | ||
| Q3 25 | $17.4M | $-10.2M | ||
| Q2 25 | $31.0M | $5.6M | ||
| Q1 25 | $25.3M | $-29.6M | ||
| Q4 24 | $38.0M | $43.7M | ||
| Q3 24 | $40.4M | $-66.8M | ||
| Q2 24 | $37.9M | $-48.3M | ||
| Q1 24 | $43.2M | $37.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 57.3% | ||
| Q3 25 | 13.2% | -6.2% | ||
| Q2 25 | 24.2% | 7.4% | ||
| Q1 25 | 21.9% | -26.9% | ||
| Q4 24 | 24.2% | 36.7% | ||
| Q3 24 | 29.8% | -60.8% | ||
| Q2 24 | 30.3% | -45.5% | ||
| Q1 24 | 27.9% | 47.2% |
| Q4 25 | 13.3% | 48.1% | ||
| Q3 25 | 9.0% | -8.8% | ||
| Q2 25 | 17.8% | 4.1% | ||
| Q1 25 | 14.8% | -23.1% | ||
| Q4 24 | 20.4% | 32.3% | ||
| Q3 24 | 21.1% | -52.4% | ||
| Q2 24 | 20.8% | -36.6% | ||
| Q1 24 | 25.1% | 27.6% |
| Q4 25 | $0.51 | $0.22 | ||
| Q3 25 | $0.37 | $-0.15 | ||
| Q2 25 | $0.64 | $-0.05 | ||
| Q1 25 | $0.51 | $-0.30 | ||
| Q4 24 | $0.74 | $0.24 | ||
| Q3 24 | $0.78 | $-0.56 | ||
| Q2 24 | $0.73 | $-0.43 | ||
| Q1 24 | $0.81 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $184.5M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $1.5B |
| Total Assets | $1.6B | $6.6B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $184.5M | ||
| Q3 25 | $276.2M | $382.6M | ||
| Q2 25 | $231.8M | $309.1M | ||
| Q1 25 | $236.9M | $356.6M | ||
| Q4 24 | $221.6M | $217.5M | ||
| Q3 24 | $250.5M | $367.1M | ||
| Q2 24 | $217.8M | $366.5M | ||
| Q1 24 | $289.6M | $541.9M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $1.5B | ||
| Q3 25 | $776.7M | $1.5B | ||
| Q2 25 | $757.5M | $1.6B | ||
| Q1 25 | $751.3M | $1.6B | ||
| Q4 24 | $732.3M | $1.6B | ||
| Q3 24 | $727.7M | $1.6B | ||
| Q2 24 | $713.3M | $1.7B | ||
| Q1 24 | $672.4M | $1.7B |
| Q4 25 | $1.6B | $6.6B | ||
| Q3 25 | $1.7B | $6.7B | ||
| Q2 25 | $1.6B | $6.8B | ||
| Q1 25 | $1.6B | $7.2B | ||
| Q4 24 | $1.6B | $7.0B | ||
| Q3 24 | $1.5B | $7.4B | ||
| Q2 24 | $1.5B | $7.5B | ||
| Q1 24 | $1.6B | $7.7B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $11.4M |
| Free Cash FlowOCF − Capex | $24.6M | $-55.2M |
| FCF MarginFCF / Revenue | 13.4% | -45.8% |
| Capex IntensityCapex / Revenue | 4.5% | 55.2% |
| Cash ConversionOCF / Net Profit | 1.35× | 0.20× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-103.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $11.4M | ||
| Q3 25 | $52.6M | $-7.6M | ||
| Q2 25 | $35.6M | $42.0M | ||
| Q1 25 | $35.1M | $-51.9M | ||
| Q4 24 | $29.0M | $55.1M | ||
| Q3 24 | $60.0M | $-5.6M | ||
| Q2 24 | $69.1M | $36.7M | ||
| Q1 24 | $55.3M | $-5.6M |
| Q4 25 | $24.6M | $-55.2M | ||
| Q3 25 | $47.2M | $-18.0M | ||
| Q2 25 | $25.0M | $29.4M | ||
| Q1 25 | $24.4M | $-59.7M | ||
| Q4 24 | $16.6M | $-76.5M | ||
| Q3 24 | $46.2M | $-27.7M | ||
| Q2 24 | $63.1M | $-500.0K | ||
| Q1 24 | $46.5M | $-57.1M |
| Q4 25 | 13.4% | -45.8% | ||
| Q3 25 | 24.6% | -15.5% | ||
| Q2 25 | 14.3% | 21.7% | ||
| Q1 25 | 14.3% | -46.5% | ||
| Q4 24 | 8.9% | -56.5% | ||
| Q3 24 | 24.1% | -21.7% | ||
| Q2 24 | 34.6% | -0.4% | ||
| Q1 24 | 27.1% | -41.9% |
| Q4 25 | 4.5% | 55.2% | ||
| Q3 25 | 2.8% | 8.9% | ||
| Q2 25 | 6.1% | 9.3% | ||
| Q1 25 | 6.3% | 6.1% | ||
| Q4 24 | 6.7% | 97.1% | ||
| Q3 24 | 7.2% | 17.3% | ||
| Q2 24 | 3.3% | 28.2% | ||
| Q1 24 | 5.1% | 37.8% |
| Q4 25 | 1.35× | 0.20× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 7.50× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | 1.26× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | -0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
KW
| Consolidated Portfolio Segment | $84.9M | 70% |
| Investment Management Fees | $30.4M | 25% |
| Real Estate | $5.1M | 4% |
